← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

10x Genomics, Inc. (TXG) 10-Year Financial Performance & Capital Metrics

TXG • • Industrial / General
HealthcareHealthcare ITGenomics & Precision MedicineGenomic Research Tools
About10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.Show more
  • Revenue $611M -1.3%
  • EBITDA -$151M +32.0%
  • Net Income -$183M +28.4%
  • EPS (Diluted) -1.52 +30.3%
  • Gross Margin 67.86% +2.6%
  • EBITDA Margin -24.7% +31.1%
  • Operating Margin -31.85% +25.7%
  • Net Margin -29.9% +27.5%
  • ROE -25.17% +23.7%
  • ROIC -31.52% +8.3%
  • Debt/Equity 0.12 -9.6%
  • Interest Coverage -48639.75 -505.0%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong Piotroski F-Score: 7/9
  • ✓Momentum leader: RS Rating 90 (top 10%)
  • ✓Strong 5Y sales CAGR of 20.0%
  • ✓Trading near 52-week high

✗Weaknesses

  • ✗Negative free cash flow

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y19.96%
3Y7.59%
TTM1.92%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM58.19%

EPS CAGR

10Y-
5Y-
3Y-
TTM59.48%

ROCE

10Y Avg-35.94%
5Y Avg-18.33%
3Y Avg-24.3%
Latest-23.74%

Peer Comparison

Genomic Research Tools
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
TXG10x Genomics, Inc.2.47B21.20-13.95-1.28%-11.89%-9.72%0.12

Profit & Loss

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+71.08M146.31M245.89M298.85M490.49M516.41M618.73M610.78M
Revenue Growth %-1.06%0.68%0.22%0.64%0.05%0.2%-0.01%
Cost of Goods Sold+10.56M28.66M61.03M58.47M74.09M120.39M209.41M196.3M
COGS % of Revenue0.15%0.2%0.25%0.2%0.15%0.23%0.34%0.32%
Gross Profit+60.52M117.65M184.86M240.38M416.4M396.02M409.31M414.48M
Gross Margin %0.85%0.8%0.75%0.8%0.85%0.77%0.66%0.68%
Gross Profit Growth %-0.94%0.57%0.3%0.73%-0.05%0.03%0.01%
Operating Expenses+78.9M135.47M213.93M325.7M469.31M563.97M674.64M609.04M
OpEx % of Revenue1.11%0.93%0.87%1.09%0.96%1.09%1.09%1%
Selling, General & Admin46.74M87.94M130.83M202.33M257.56M298.3M343.33M344.34M
SG&A % of Revenue0.66%0.6%0.53%0.68%0.53%0.58%0.55%0.56%
Research & Development32.16M47.54M83.1M123.38M211.75M265.67M270.33M264.7M
R&D % of Revenue0.45%0.32%0.34%0.41%0.43%0.51%0.44%0.43%
Other Operating Expenses137K-249K000060.98M0
Operating Income+-18.38M-110.76M-29.07M-85.32M-52.91M-167.94M-265.33M-194.56M
Operating Margin %-0.26%-0.76%-0.12%-0.29%-0.11%-0.33%-0.43%-0.32%
Operating Income Growth %--5.03%0.74%-1.94%0.38%-2.17%-0.58%0.27%
EBITDA+-14.07M-106.86M-22M-66.3M-24.66M-134.94M-221.71M-150.85M
EBITDA Margin %-0.2%-0.73%-0.09%-0.22%-0.05%-0.26%-0.36%-0.25%
EBITDA Growth %--6.59%0.79%-2.01%0.63%-4.47%-0.64%0.32%
D&A (Non-Cash Add-back)4.3M3.9M7.07M19.02M28.25M33.01M43.62M43.71M
EBIT-17.93M-109.99M-27.95M-532.79M-52.85M-161.5M-248.73M-177.7M
Net Interest Income+-503K-1.39M-274K-150K-660K6.17M16.87M18.44M
Interest Income308K1.02M2.81M1.53M206K6.65M16.91M18.45M
Interest Expense811K2.41M3.08M1.68M866K476K33K4K
Other Income/Expense-366K-1.63M-1.96M-449.15M-802K5.97M16.57M16.86M
Pretax Income+-18.74M-112.4M-31.03M-534.48M-53.72M-161.97M-248.76M-177.7M
Pretax Margin %-0.26%-0.77%-0.13%-1.79%-0.11%-0.31%-0.4%-0.29%
Income Tax+21K87K218K8.26M4.51M4.03M6.34M4.93M
Effective Tax Rate %1%1%1.01%1.02%1.08%1.02%1.03%1.03%
Net Income+-18.76M-112.48M-31.25M-542.73M-58.22M-166M-255.1M-182.63M
Net Margin %-0.26%-0.77%-0.13%-1.82%-0.12%-0.32%-0.41%-0.3%
Net Income Growth %--5%0.72%-16.37%0.89%-1.85%-0.54%0.28%
Net Income (Continuing)-18.76M-112.48M-31.25M-542.73M-58.22M-166M-255.1M-182.63M
Discontinued Operations00000000
Minority Interest00000000
EPS (Diluted)+-1.62-8.40-0.80-5.37-0.53-1.46-2.18-1.52
EPS Growth %--4.19%0.9%-5.71%0.9%-1.75%-0.49%0.3%
EPS (Basic)-1.62-8.40-0.80-5.37-0.53-1.46-2.18-1.52
Diluted Shares Outstanding11.59M13.39M39.09M101.15M110.35M113.86M117.17M120.45M
Basic Shares Outstanding11.59M13.39M39.06M101.15M110.35M113.86M117.17M120.45M
Dividend Payout Ratio--------

Balance Sheet

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+68.11M106.24M480.84M774.37M747.59M635.03M596.02M584.39M
Cash & Short-Term Investments47.86M65.08M424.17M663.6M587.45M429.98M388.69M393.4M
Cash Only47.86M65.08M424.17M663.6M587.45M219.75M359.28M344.07M
Short-Term Investments00000210.24M29.41M49.34M
Accounts Receivable13.34M28.09M33.37M51.21M85.25M104.21M114.83M87.86M
Days Sales Outstanding68.570.0749.5462.5463.4473.6667.7452.51
Inventory4.84M8.57M15.27M29.96M59.97M81.63M73.71M83.11M
Days Inventory Outstanding167.22109.1491.32187.03295.42247.49128.47154.53
Other Current Assets2.07M0016.57M1.03M19.21M18.79M20.02M
Total Non-Current Assets+7.5M18.07M125.08M154.97M271.24M393.94M369.12M334.25M
Property, Plant & Equipment6.92M11.13M48.82M119.82M230.41M359.21M344.93M309.94M
Fixed Asset Turnover10.26x13.15x5.04x2.49x2.13x1.44x1.79x1.97x
Goodwill00004.51M4.51M4.51M4.51M
Intangible Assets0022.37M22.35M25.4M22.86M16.62M15.67M
Long-Term Investments05.01M000000
Other Non-Current Assets577K1.94M53.9M12.8M10.92M7.37M3.06M4.13M
Total Assets+75.61M124.31M605.92M929.34M1.02B1.03B965.14M918.64M
Asset Turnover0.94x1.18x0.41x0.32x0.48x0.50x0.64x0.66x
Asset Growth %-0.64%3.87%0.53%0.1%0.01%-0.06%-0.05%
Total Current Liabilities+22.14M32.36M63.05M118.13M110.36M130.96M127.16M117.63M
Accounts Payable5.44M8.79M13.03M4.71M17.35M21.6M15.74M12.91M
Days Payables Outstanding188.13111.9777.9129.485.4865.4927.4324
Short-Term Debt4.22M4.19M9.88M00000
Deferred Revenue (Current)1000K1000K1000K1000K1000K1000K1000K1000K
Other Current Liabilities6.72M9.2M15.56M21.63M40.91M29.74M33.96M41.84M
Current Ratio3.08x3.28x7.63x6.56x6.77x4.85x4.69x4.97x
Quick Ratio2.86x3.02x7.38x6.30x6.23x4.23x4.11x4.26x
Cash Conversion Cycle47.5967.2462.94220.17273.38255.66168.78183.03
Total Non-Current Liabilities+165.98M311.94M122.79M72.14M90.9M92.28M96.94M90.87M
Long-Term Debt6.33M25.49M19.84M00000
Capital Lease Obligations00057.04M76.85M86.14M83.85M73.33M
Deferred Tax Liabilities158.41M284.57M000000
Other Non-Current Liabilities514K771K102.12M15.1M14.05M2.98M4.28M5.03M
Total Liabilities188.12M344.3M185.84M190.27M201.26M223.24M224.1M208.5M
Total Debt+10.56M29.68M29.72M62.98M81.98M95.18M95.37M82.61M
Net Debt-37.3M-35.4M-394.45M-600.63M-505.47M-124.57M-263.91M-261.45M
Debt / Equity--0.07x0.09x0.10x0.12x0.13x0.12x
Debt / EBITDA--------
Net Debt / EBITDA--------
Interest Coverage-22.66x-45.98x-9.44x-50.73x-61.10x-352.82x-8040.27x-48639.75x
Total Equity+-112.51M-219.99M420.08M739.07M817.57M805.74M741.04M710.13M
Equity Growth %--0.96%2.91%0.76%0.11%-0.01%-0.08%-0.04%
Book Value per Share-9.71-16.4310.757.317.417.086.325.90
Total Shareholders' Equity-112.51M-219.99M420.08M739.07M817.57M805.74M741.04M710.13M
Common Stock1K1K2K2K2K2K2K2K
Retained Earnings-118.63M-231.12M-262.37M-805.1M-863.32M-1.03B-1.28B-1.47B
Treasury Stock00000000
Accumulated OCI-15K-37K-46K-50K22K-4.33M-429K-493K
Minority Interest00000000

Cash Flow

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-10.7M-76.41M34.63M-217.9M-21.37M-33.61M-15.2M6.66M
Operating CF Margin %-0.15%-0.52%0.14%-0.73%-0.04%-0.07%-0.02%0.01%
Operating CF Growth %--6.14%1.45%-7.29%0.9%-0.57%0.55%1.44%
Net Income-18.76M-112.48M-31.25M-542.73M-58.22M-166M-255.1M-182.63M
Depreciation & Amortization4.3M3.9M7.07M19.02M28.25M33.01M43.62M43.71M
Stock-Based Compensation1.66M2.66M13.33M48.63M95.96M136.85M166.95M140.75M
Deferred Taxes0251K614K1.55M0000
Other Non-Cash Items149K1.25M101K306.02M79K1.96M11.99M3.58M
Working Capital Changes1.95M28.02M44.76M-50.38M-87.44M-39.42M17.34M1.25M
Change in Receivables-5.13M-14.75M-5.28M-17.85M-34.04M-18.95M-10.61M26.95M
Change in Inventory-2M-3.73M-6.7M-14.6M-30.13M-21.19M7.87M-9.78M
Change in Payables3.03M2.59M4.9M-7.77M11.08M5.86M-6.02M-3.35M
Cash from Investing+-3.76M-6.71M-42.77M-38.39M-106.73M-350.89M133.49M-32.63M
Capital Expenditures-3.76M-6.71M-42.77M-38.39M-101.28M-131.66M-48.6M-12.39M
CapEx % of Revenue0.05%0.05%0.17%0.13%0.21%0.25%0.08%0.02%
Acquisitions--------
Investments--------
Other Investing0-425K0000-923K-1M
Cash from Financing+20.58M105.37M414.59M468.91M35.3M15.82M13.67M10.91M
Debt Issued (Net)--------
Equity Issued (Net)--------
Dividends Paid00000000
Share Repurchases--------
Other Financing1.09M1.8M3.77M23.74M0000
Net Change in Cash--------
Free Cash Flow+-14.46M-83.12M-8.14M-256.29M-122.65M-165.27M-64.72M-5.73M
FCF Margin %-0.2%-0.57%-0.03%-0.86%-0.25%-0.32%-0.1%-0.01%
FCF Growth %--4.75%0.9%-30.49%0.52%-0.35%0.61%0.91%
FCF per Share-1.25-6.21-0.21-2.53-1.11-1.45-0.55-0.05
FCF Conversion (FCF/Net Income)0.57x0.68x-1.11x0.40x0.37x0.20x0.06x-0.04x
Interest Paid01.82M2.25M1.67M1.22M841K436K0
Taxes Paid06K22K280K8.66M3.92M4.93M5.64M

Key Ratios

Metric20172018201920202021202220232024
Return on Equity (ROE)---31.24%-93.64%-7.48%-20.45%-32.98%-25.17%
Return on Invested Capital (ROIC)---85.05%-78%-17.62%-25.36%-34.36%-31.52%
Gross Margin85.14%80.41%75.18%80.44%84.89%76.69%66.15%67.86%
Net Margin-26.39%-76.88%-12.71%-181.61%-11.87%-32.15%-41.23%-29.9%
Debt / Equity--0.07x0.09x0.10x0.12x0.13x0.12x
Interest Coverage-22.66x-45.98x-9.44x-50.73x-61.10x-352.82x-8040.27x-48639.75x
FCF Conversion0.57x0.68x-1.11x0.40x0.37x0.20x0.06x-0.04x
Revenue Growth-105.83%68.06%21.53%64.13%5.28%19.81%-1.28%

Revenue by Segment

201920202021202220232024
Consumables206.88M252.69M418.74M435.59M479.55M493.43M
Consumables Growth-22.14%65.72%4.02%10.09%2.89%
Instruments----123.47M92.72M
Instruments Growth------24.91%
Service4.07M6.03M7.28M8.43M15.7M24.64M
Service Growth-48.21%20.62%15.79%86.39%56.90%
Instuments34.95M40.13M64.47M72.4M--
Instuments Growth-14.83%60.67%12.29%--

Revenue by Geography

201920202021202220232024
Americas----373.19M347.76M
Americas Growth------6.81%
EMEA58M73.27M108.49M117.07M142.28M159.76M
EMEA Growth-26.31%48.08%7.91%21.53%12.29%
CHINA29.92M41.74M74.92M59.56M50.97M57.3M
CHINA Growth-39.51%79.50%-20.51%-14.43%12.43%
Asia-Pacific, Excluding China--42.09M-52.29M45.96M
Asia-Pacific, Excluding China Growth------12.12%
UNITED STATES---284.99M--
UNITED STATES Growth------
Asia Pacific18.21M24.51M-46M--
Asia Pacific Growth-34.57%----
Americas, Excluding United States---8.79M--
Americas, Excluding United States Growth------
North America139.76M159.33M258.27M---
North America Growth-14.01%62.10%---

Frequently Asked Questions

Growth & Financials

10x Genomics, Inc. (TXG) reported $641.8M in revenue for fiscal year 2024. This represents a 803% increase from $71.1M in 2017.

10x Genomics, Inc. (TXG) saw revenue decline by 1.3% over the past year.

10x Genomics, Inc. (TXG) reported a net loss of $76.3M for fiscal year 2024.

Dividend & Returns

10x Genomics, Inc. (TXG) has a return on equity (ROE) of -25.2%. Negative ROE indicates the company is unprofitable.

10x Genomics, Inc. (TXG) generated $81.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.